Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.54 |
| ▸ | RAB9A | P51151 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | AR | P10275 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505379 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL16896533 | 0.84 | RAB9A (0.54) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL20398262 | 0.82 | RAB9A (0.48) | SMN1; SMN2RAB9ANPC1MAPTHPGD | |
| SCHEMBL29855755 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL29855600 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL29505245 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL16896582 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL29505280 | 0.76 | HRH3 (0.60) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL16896509 | 0.76 | HRH3 (0.60) | SMN1; SMN2RAB9ANPC1MAPTALOX15 | |
| SCHEMBL16896310 | 0.75 | KMT2A (0.48) | RAB9AGAAALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-09-09 | — | — | US | disclosed |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-09-05 | — | — | US | disclosed |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2024-05-14 | — | — | US | disclosed |
| EP-4353324-A2 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-04-17 | — | — | EP | disclosed |
| US-20230391774-A1 | Novel Compounds | AC IMMUNE SA (CH) | 2023-12-07 | — | — | US | disclosed |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-10-19 | — | — | US | disclosed |
| CN-116568684-A | Novel compounds | AC免疫有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-04 | — | — | US | disclosed |
| WO-2022078971-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2022-04-21 | — | — | WO | disclosed |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-12-27 | — | — | US | disclosed |
| EP-3094329-B1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2018-09-26 | — | — | EP | disclosed |
| US-20180208605-A1 | Substituted Aza Compounds as IRAK-4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-07-26 | — | — | US | disclosed |
| EP-3322409-A1 | SUBSTITUTED AZA COMPOUNDS AS IRAK-4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-05-23 | — | — | EP | disclosed |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-9732095-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-15 | — | — | US | disclosed |
| WO-2017009806-A1 | SUBSTITUTED AZA COMPOUNDS AS IRAK-4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-01-19 | — | — | WO | disclosed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | disclosed |
| EP-3094329-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015104688-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1090/4885RAB9A 3927/4885NPC1 1258/4885 |
| US-20180208605-A1 | Substituted Aza Compounds as IRAK-4 Inhibitors | IRAK4, IRAK2, IRAK1 | SMN1; SMN2 1924/4885RAB9A 2855/4885NPC1 1968/4885 |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1309/4885RAB9A 4067/4885NPC1 1422/4885 |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1309/4885RAB9A 4067/4885NPC1 1422/4885 |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | SMN1; SMN2 988/4885RAB9A 3739/4885NPC1 1097/4885 |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1090/4885RAB9A 3927/4885NPC1 1258/4885 |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1090/4885RAB9A 3927/4885NPC1 1258/4885 |
| US-12410193-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1309/4885RAB9A 4067/4885NPC1 1422/4885 |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1309/4885RAB9A 4067/4885NPC1 1422/4885 |
| US-20230391774-A1 | Novel Compounds | MAPT, PSEN2, PSEN1 | SMN1; SMN2 497/4885RAB9A 1846/4885NPC1 195/4885 |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | SMN1; SMN2 1309/4885RAB9A 4067/4885NPC1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.